Karyopharm Therapeutics Inc. Q4 2022 Earnings Call Transcript
KPTI Stock | USD 0.72 0.01 1.37% |
Under 61% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
Karyopharm Therapeutics Inc. Q4 2022 Earnings Call Transcript February 15, 2023 Operator Good day. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. . Please be advised that
Read at finance.yahoo.com
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
GOSS | Gossamer Bio | 28.17 | ||||
ASMB | Assembly Biosciences | 1.86 | ||||
PMVP | Pmv Pharmaceuticals | 0.64 | ||||
ABOS | Acumen Pharmaceuticals | 0.46 | ||||
NUVB | Nuvation Bio | 1.11 | ||||
NVCT | Nuvectis Pharma | 1.49 | ||||
KRON | Kronos Bio | 1.96 | ||||
BLUE | Bluebird Bio | 2.56 | ||||
MREO | Mereo BioPharma | 3.12 | ||||
REPL | Replimune | 3.32 | ||||
HOOK | Hookipa Pharma | 3.60 | ||||
LYRA | Lyra Therapeutics | 4.76 | ||||
CTMX | CytomX Therapeutics | 5.08 | ||||
GBIO | Generation Bio | 6.30 | ||||
RLYB | Rallybio Corp | 6.67 | ||||
GLUE | Monte Rosa | 8.46 | ||||
AGIO | Agios Pharm | 11.99 | ||||
MRSN | Mersana Therapeutics | 14.18 | ||||
XFOR | X4 Pharmaceuticals | 21.05 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |